Our projectsBrilliant scientists, powerful collaborations. We find and fund projects that are ripe for treating Duchenne now.
DMD Care UK
Access to best care for everyone with Duchenne.
Combating immunity to AAV
Ensuring as many patients as possible can benefit from gene therapy.
A ground-breaking programme for exploring gene therapy for Duchenne.
An alternative to existing steroid treatments for Duchenne.
CRISPR for Duchenne
Gene editing technology to correct mutated dystrophin gene.
Gene therapy for Becker
A microdystrophin gene therapy approach for Becker muscular dystrophy.
Activity monitoring biomarker
KINEDMD: Wearable sensor technology to monitor Duchenne patients’ activity.
A next-generation gene therapy delivery approach.
Grants to support clinical and research staff and facilities
Awards for up-and-coming researchers
Measuring disease progression and response to new treatments.
Dystrophic dogs provide insights into Duchenne research.
This project focuses on targeting inflammation and fibrosis – two key challenges in Duchenne.
Pre-clinical research for drug to target muscle fibrosis.
Non-invasive imaging biomarker
Reducing biopsies and improving dystrophin analysis in Duchenne boys.
Increasing utrophin to compensate for dystrophin.
We are passionate about supporting the most promising research to find therapies and a cure for Duchenne muscular dystrophy. We aim to focus our efforts on tackling Duchenne for all sufferers, regardless of their type of mutation. We have an open grant call and all applications are peer reviewed.
Our scientific advisory board comprises leading minds in the field: Professor Ronald Cohn, Dr Kevin Campbell, Professor Madeleine Durbeej-Hjalt and Dr James Dowling together with our Honorary Scientific Patron Professor Victor Dubowitz. Read more about their work here. Please contact research [at] duchenne.org.uk for more information about applications.
We aim to stop Duchenne muscular dystrophy being a death sentence for hundreds of thousands of boys worldwide.
We are helping turn the hope of treatments into reality. Critical supportive drugs are in clinical trial thanks to our funds.
In the last 4 years we have given more than £3m to ground-breaking research projects.
And there is still work to do.